Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

NCT06639256

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Sichuan Huiyu Pharmaceutical Co., Ltd
Enrollment	258 participants

Key Eligibility Criteria

Inclusion (8)

- Written informed consent;
- e18years old and d80 years old, gender: male or female;
- Histologically or cytologically confirmed unresectable advanced/metastatic solid tumor that has relapsed or progressed on or after standard systemic treatments, or refused the standard treatment, or for which no standard treatment is available;
- Presence of at least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1;
- Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1;

... and 3 more (see full listing online)

Exclusion (21)

- Within the defined washout periods for prior anti-cancer treatments;
- Participant is currently participating or has participated in a study of an investigational agent or using an investigational device within 4 weeks of first dose of HY07121.
- Any other malignancy within 2 years prior to the first dose of the study treatment except for localized cancers that are considered to have been cured and in the opinion of the Investigator present a low risk for recurrence.
- Participant has not recovered (i.e., to Grade 1 or to baseline) from previous anticancer therapy-induced Adverse Events (AEs).
- Participants with a history of recently (within previous 2 years of the first dose of the study treatment) active diverticulitis or symptomatic peptic ulcer disease;

... and 16 more (see full listing online)

Locations (1 total)

Cancer Hospital of Shandong First Medical University, Jinan, China